# Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

> **NCT05824468** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (actual)

## Conditions studied

- Cervical Cancer
- Cervical Carcinoma

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05824468
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-10
- **Primary completion:** 2024-07-20
- **Final completion:** 2026-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824468, "Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05824468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*